Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Active, not recruiting · NCT05458674 · Registry updated 2026-07-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-07-10 | NCT05458674 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Criterium, Inc. | 5 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Care Northwest | Spokane Valley | United States | 5 |
| George Washington Medical Faculty Associates | Washington D.C. | United States | 3 |
| New Mexico Cancer Care Alliance | Albuquerque | United States | 3 |
| Swedish Cancer Institute | Issaquah | United States | 2 |
| University of Colorado | Aurora | United States | 147 |
| University of Wisconsin Carbone Cancer Center | Madison | United States | 58 |